Dr. Doris Quon, MD

Claim this profile

Orthopaedic Institute for Children

Studies Hemophilia
Studies Hemophilia B
4 reported clinical trials
4 drugs studied

Affiliated Hospitals

Image of trial facility.
Orthopaedic Institute For Children
Image of trial facility.
Orthopaedic Institute For Children Hemophilia Program

Clinical Trials Doris Quon, MD is currently running

Image of trial facility.

Natural History Study

for Blood Disorders

In parallel with the growth of American Thrombosis and Hemostasis Network's (ATHN) clinical studies, the number of new therapies for all congenital and acquired hematologic conditions, not just those for bleeding and clotting disorders, is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have yet to demonstrate long-term safety and effectiveness beyond the pivotal trials that led to their approval. In addition, results from well-controlled, pivotal studies often cannot be replicated once a therapy has been approved for general use.(1,2,3,4) In 2019 alone, the United States Food and Drug Administration (FDA) has issued approvals for twenty-four new therapies for congenital and acquired hematologic conditions.(5) In addition, almost 10,000 new studies for hematologic diseases are currently registered on www.clinicaltrials.gov.(6) With this increase in potential new therapies on the horizon, it is imperative that clinicians and clinical researchers in the field of non-neoplastic hematology have a uniform, secure, unbiased, and enduring method to collect long-term safety and efficacy data. ATHN Transcends is a cohort study to determine the safety, effectiveness, and practice of therapies used in the treatment of participants with congenital or acquired non-neoplastic blood disorders and connective tissue disorders with bleeding tendency. The study consists of 7 cohorts with additional study "arms" and "modules" branching off from the cohorts. The overarching objective of this longitudinal, observational study is to characterize the safety, effectiveness and practice of treatments for all people with congenital and acquired hematologic disorders in the US. As emphasized in a recently published review, accurate, uniform and quality national data collection is critical in clinical research, particularly for longitudinal cohort studies covering a lifetime of biologic risk.(7)
Recruiting1 award N/A1 criteria
Image of trial facility.

SEVENFACT®

for Hemophilia

Phase IV multi-center, US-centric, open-label, safety study enrolling participants with Hemophilia A or B with inhibitors, 12 years of age and older, who are either on long term prophylactic treatment (e.g., emicizumab) at risk of experiencing a breakthrough bleeding event (BE), or who are not on prophylactic treatment who may need to control a BE.
Recruiting3 awards Phase 46 criteria

More about Doris Quon, MD

Clinical Trial Related5 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Doris Quon, MD has experience with
  • Liver Transplantation
  • Coagulation Factor VIIa [recombinant]-jncw
  • ATHN Transcends
  • SPK-8016

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Doris Quon, MD specialize in?
Is Doris Quon, MD currently recruiting for clinical trials?
Are there any treatments that Doris Quon, MD has studied deeply?
What is the best way to schedule an appointment with Doris Quon, MD?
What is the office address of Doris Quon, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security